Xiao-Kun Li

Dr. Xiao-Kun Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
XLXiao-Kun Li
Xiao-Kun Li
LCLingmin Chen
Lingmin Chen
SLSiyuan Luan
Siyuan Luan
JZJianfeng Zhou
Jianfeng Zhou
XXXin Xiao
Xin Xiao
YYYong Yuan
Yong Yuan

1 June 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ZCZhuangzhuang Cong
Zhuangzhuang Cong
YDYifei Diao
Yifei Diao
XLXiao-Kun Li
Xiao-Kun Li
ZJZhisheng Jiang
Zhisheng Jiang
YXYang Xu
Yang Xu
YSYi Shen
Yi Shen

25 June 2020 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
XLXiao-Kun Li
Xiao-Kun Li
YXYang Xu
Yang Xu
HZHai Zhou
Hai Zhou
ZCZhuang-Zhuang Cong
Zhuang-Zhuang Cong
WWWen-Jie Wu
Wen-Jie Wu
YSYi Shen
Yi Shen
Although robotic techniques have been used for oesophagectomy for many years, whether robot-assisted minimally invasive oesophagectomy (RAMIE) can actually improve outcomes and surpass thoraco-laparoscopic minimally invasive oesophagectomy (MIE) in the success rate of lymph node dissection remains to be empirically demonstrated. Therefore, we performed this systematic review and meta-analysis of case–control studies to systematically compare the effect of lymph node dissection and the incidence of vocal cord palsy between RAMIE and MIE. The PubMed, EMBASE, and Web of Science databases were systematically searched up to December 1, 2019, for case–control studies that compared RAMIE with MIE. Thirteen articles were included, with a total of 1,749 patients with esophageal cancer, including 866 patients in the RAMIE group and 883 patients in the MIE group. RAMIE yielded significantly larger numbers of total dissected lymph nodes (WMD = 1.985; 95% CI, 0.448–3.523; P = 0.011) and abdominal lymph nodes (WMD = 1.686; 95% CI, 0.420–2.951; P = 0.009) as well as lymph nodes along RLN (WMD = 0.729; 95% CI, 0.348–1.109; P < 0.001) than MIE. Additionally, RAMIE could significantly decrease estimated blood loss (WMD = -11.208; 95% CI, -19.358 to -3.058; P = 0.007) and the incidence of vocal cord palsy (OR = 0.624; 95% CI, 0.411–0.947; P = 0.027) compared to MIE. Compared with MIE, RAMIE resulted in a higher total lymph node yield and a higher lymph node yield in the abdomen and along RLN, along with reduced blood loss during surgery and the incidence of vocal cord palsy. Therefore, RAMIE could be considered to be a standard treatment, with less blood loss, lower incidence of vocal cord palsy, and more radical lymph node dissection, exhibiting superiority over MIE.

1 April 2021 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
CZChi Zhang
Chi Zhang
XLXiao-Kun Li
Xiao-Kun Li
ZCZhuang-Zhuang Cong
Zhuang-Zhuang Cong
CZChao Zheng
Chao Zheng
CLChao Luo
Chao Luo
YSYi Shen
Yi Shen
Controlling nutritional status is a prognostic factor for patients with lung cancer: a systematic review and meta-analysis Chi Zhang, Xiao-Kun Li, Zhuang-Zhuang Cong, Chao Zheng, Chao Luo, Kai Xie, Yang Xu, Wen-Feng Gu, Yong Qiang, Yi Shen

28 November 2023 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
XLXiao-Kun Li
Xiao-Kun Li
JLJiamei Li
Jiamei Li
SHSiqin He
Siqin He
SLSiyuan Luan
Siyuan Luan
HZHaowen Zhang
Haowen Zhang
YYYong Yuan
Yong Yuan

25 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
HZHaowen Zhang
Haowen Zhang
HZHuifen Zhu
Huifen Zhu
YPYuhao Peng
Yuhao Peng
SLSiyuan Luan
Siyuan Luan
XLXiao-Kun Li
Xiao-Kun Li
YYYong Yuan
Yong Yuan
Background: The application of liquid biopsy analysis utilizing circulating tumor DNA (ctDNA) has gained prominence as a biomarker in specific cancer types. Nevertheless, the correlation between ctDNA and the prognostic outcomes of patients with esophageal cancer (EC) remains a subject of controversy. This meta-analysis aims to assess the correlation between ctDNA and the prognosis of EC patients. Methods: The authors systematically explored Embase, PubMed, and the Cochrane Database to identify studies reporting on the prognostic value of ctDNA in EC patients before November 2023. The primary outcome involved the determine of associations between ctDNA with overall survival (OS), disease-free survival (DFS)/recurrence-free survival (RFS), as well asprogression-free survival (PFS) among EC patients. Secondary outcomes encompassed a detailed subgroup analysis in the setting of EC, including parameters such as detection time, histological subtypes, treatment modalities, regions, anatomic locations, and detection methods. Publication bias was assessed utilizing Begg’s test, Egger’s test, and funnel plots. A sensitivity analysis was conducted by systematically excluding individual studies to evaluate the stability of the results. Results: A total of 1203 studies were initially screened, from which 13 studies underwent further analysis, encompassing 604 patients diagnosed with EC. The comprehensive pooled analysis indicated a significant association between the detection of ctDNA and poor OS (HR: 3.65; 95% CI: 1.97–6.75, P<0.001), DFS/RFS (HR: 6.08; 95% CI: 1.21–30.50, P<0.001), and PFS (HR: 2.84; 95% CI: 1.94–4.16, P<0.001). Subgroup analysis showed that ctDNA remained a consistent negative predictor of OS when stratified by different detection time, histological subtypes, regions, anatomic locations, and detection methods. Furthermore, subgroup analysis stratified by regions and study types demonstrated an association between ctDNA detection and poor PFS in EC patients. Conclusion: Our results indicate plasma ctDNA may serve as robust prognostic markers for OS, DFS/RFS, and PFS among EC patients. This finding suggests that plasma ctDNA could offer a highly effective approach for risk stratification and personalized medicine.